Home › Research › Prevention trials
Prevention of cognitive impairment and dementia in people with Parkinson's disease: A call-to-action
Elke Kalbe, Tobias Warnecke, Carsten Eggers, Anja Ophey, Ann‐Kristin Folkerts. Journal of Parkinson s Disease, 2025-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Mild cognitive impairment and dementia are common symptoms in people with Parkinson's disease (PwPD) that impair the quality of life of those affected. However, PD-specific concepts for the prevention of cognitive decline are rarely incorporated into routine care. Here, we provide key data on cognitive impairment in PwPD and a framework for primary, secondary, and tertiary prevention in this context. The importance of cognitive reserve as a protective buffer for cognitive decline in PwPD is highlighted. Relevant lifestyle and health-related factors, including cognitive aspects, physical and social activity, diet, hearing loss, and cardiovascular factors, are discussed. Evidence on the efficacy of possible cognition-enhancing interventions in PwPD-pharmacological, cognitive, physical, nutritional, and multidomain interventions-is summarized. On this basis, and the recommendations of the European Task Force for Brain Health Services, a proposal is developed outlining options for preventing cognitive impairment in PwPD that could be implemented in routine care, as well as further developments needed to achieve a best-case scenario. The main pillars of a strategic agenda for this purpose include: (i) regular assessment of cognitive state, overall risk, and risk factors for cognitive decline; (ii) risk communication and education concerning modifiable risk factors with standardized procedures; (iii) risk reduction with multi-domain interventions for secondary prevention; and (iv) cognitive enhancement with cognitive and physical training for tertiary prevention. As the proposal makes clear, the prevention of cognitive impairment in PwPD requires interdisciplinary collaboration organized throughout PD care networks.
What this study adds
Evidence grade: Low
This call-to-action paper proposes a framework for preventing cognitive impairment in people with Parkinson's disease, covering lifestyle factors such as physical and social activity, diet, hearing loss, and cardiovascular factors. It recommends regular cognitive assessment, risk communication, and multidomain risk reduction, but does not report new trial results.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kalbe, E., Warnecke, T., Eggers, C., Ophey, A., & Folkerts, A. (2025). Prevention of cognitive impairment and dementia in people with Parkinson's disease: A call-to-action. Journal of Parkinson s Disease. https://doi.org/10.1177/1877718x251365769
Vancouver
Kalbe E, Warnecke T, Eggers C, Ophey A, Folkerts A. Prevention of cognitive impairment and dementia in people with Parkinson's disease: A call-to-action. Journal of Parkinson s Disease. 2025. doi:10.1177/1877718x251365769. PMID: 41032653.
BibTeX
@article{kalbe2025-41032653,
author = {Kalbe, Elke and Warnecke, Tobias and Eggers, Carsten and Ophey, Anja and Folkerts, Ann‐Kristin},
title = {{Prevention of cognitive impairment and dementia in people with Parkinson's disease: A call-to-action}},
journal = {Journal of Parkinson s Disease},
year = {2025},
doi = {10.1177/1877718x251365769},
pmid = {41032653},
url = {https://doi.org/10.1177/1877718x251365769}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The main pillars of a strategic agenda for this purpose include: (i) regular assessment of cognitive state, overall risk, and risk factors for cognitive decline; (ii) risk communication and education concerning modifiable risk factors with standardized procedures; (iii) risk reduction with multi-domain interventions for secondary prevention; and (iv) cognitive enhancement with cognitive and physical training for tertiary prevention.
Why it matters
This call-to-action paper proposes a framework for preventing cognitive impairment in people with Parkinson's disease, covering lifestyle factors such as physical and social activity, diet, hearing loss, and cardiovascular factors. It recommends regular cognitive assessment, risk communication, and multidomain risk reduction, but does not report new trial results.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Parkinson s Disease) |
| Journal's citation record | 1 / 4 | Journal of Parkinson s Disease: journal h-index 97 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Ann‐Kristin Folkerts: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Cologne: institution h-index 879 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41032653) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/1877718x251365769
- PubMed: 41032653
- Original source →
- Free full text: Journal of Parkinson s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Related studies in Prevention trials from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.